Drug intelligence / Profile preview

Tifblue blueberry extract

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

Tifblue blueberry extract is a phytochemical-rich substance derived from the 'Tifblue' cultivar of the Rabbiteye blueberry (*Vaccinium ashei*). It is primarily studied for its anticarcinogenic and antimutagenic properties. In vitro research has demonstrated that ethanol and acetone/water extracts of Tifblue blueberries significantly inhibit the proliferation of various cancer cell lines, including cervical cancer (CaSki, SiHa) and breast cancer (MCF-7, T47-D). The extract's bioactivity is attributed to its high concentration of polyphenols, such as anthocyanins and flavonols, which act as antioxidants and modulate cellular pathways involved in carcinogenesis and mutagenesis.

Other names: Vaccinium ashei 'Tifblue' extractRabbiteye blueberry extract

Targets

DNA

Beyond the preview

Go deeper on Tifblue blueberry extract.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tifblue blueberry extract.

Explore the full profile